

Docket No: 25401-40
CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents,

P.O. Box 1450; Alexandria, VA 22313-1450 on Occ 19, 7005

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Magnus Ingelman-Sundberg et al

Paper No.

Serial No.:

10/532,014

Group Art Unit:

Filing Date:

April 20, 2005

Examiner:

For:

The Use of Cytochrome P450 Enzyme CYP2W1 as a Drug Target for Cancer

Therapy Papillomavirus

RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures dated November 2, 2005, submitted herewith are: (1) Paper and computer-readable forms of the Sequence Listing; (2) Statement of Sequence Listing Identity; and (3) a copy of the Notification.

Also enclosed is a Declaration and Power of Attorney signed by the Inventors. The surcharge for late filing of the Declaration and Power of Attorney was paid April 20, 2005.

Please charge any additional fees required in connection with this communication to Deposit Account No. 04-1133.

Respectfully submitted,

Holly D. Kozlowski, Reg. No. 30,468

DINSMORE & SHOHL LLP

1900 Chemed Center 255 E. Fifth Street

Cincinnati, Ohio 45202

(513) 977-8568





United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Sox 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

OC000000017358960

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	,	ATTY, DOCKET NO.	
10/532,014	Magnus Ingelman-Sundberg	g	25401-40	
24256 DINSMORE & SHOHL, LLP 1900 CHEMED CENTER	[INTERNATIONAL APPLICATION NO.		
	- -	PCT/SE03/01652		
	118-05	I.A. FILING DATE	PRIORITY DATE	
	Seq. 118t	10/24/2003	10/24/2002	
255 EAST FIFTH STREET	1-2-06			
CINCINNATI, OH 45202	0LA	CONFIRMATION NO. 8991 371 FORMALITIES LETTER		
	3 1001 (17)			
	0101-90			

Date Mailed: 11/02/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(q), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8. 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed



A copy of this notice **MUST** be returned with the response.

CHARITTA A BURT

Telephone: (703) 308-9140 EXT 207

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/532,014	PCT/SE03/01652	25401-40

FORM PCT/DO/EO/922 (371 Formalities Notice)